Discussion
toxicities, pancreatic cancer
RECURRENT PROSTATE CANCER, PANCREATIC CANCER, PROSTATE CANCER, PROSTATE ADENOCARCINOMA
The goal of this phase-1 clinical study was to estimate the maximum tolerated dose of oncolytic, cytotoxic Ad5-IL-12 gene therapy in men with recurrent prostate adenocarcinoma. Patients were administered increasing doses of Ad5-IL-12, ranging from 1 × 10Investigators from our institution have successfully carried out five phase-I and a phase I/II clinical study utilizing ‘in-house’ developed replication competent, oncolytic adenoviruses in newly diagnosed and locally recurrent prostate cancer [Akin to the findings in the pancreatic cancer trial that was conducted with the same adenoviral vector [IL-12 is known to mediate the interaction between innate and adaptive immunity [Serum PSA levels and PSA doubling time (PSADT) are key markers of prostate cancer. We followed PSA in patients before and after gene therapy and estimated PSADT. Although, we observed an initial decrease in PSA in 8 out of 14 patients (>20% decrease; Earlier trials failed to deliver on the promise of a potent proinflammatory cytokine due to toxicities associated with its systemic delivery. Localized IL-12 delivery provides enhanced spatiotemporal distribution, generates systemic antitumor immunity from a locally initiated immune response, brings rapid increase in pro-inflammatory cytokines, including IFN-γ, and IL-6, and reduces opposing negative signaling [